Mohit Bansal
Stock Analyst at Wells Fargo
(4.04)
# 466
Out of 4,944 analysts
165
Total ratings
60%
Success rate
8.7%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Upgrades: Overweight | $460 | $395.92 | +16.19% | 11 | Aug 6, 2025 | |
| BNTX BioNTech SE | Maintains: Overweight | $170 → $150 | $112.78 | +33.00% | 2 | Aug 5, 2025 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $97 → $90 | $82.71 | +8.81% | 11 | Jul 30, 2025 | |
| REGN Regeneron Pharmaceuticals | Downgrades: Equal-Weight | $700 → $580 | $561.55 | +3.29% | 18 | May 30, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $50 → $47 | $37.67 | +24.77% | 2 | May 13, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Equal-Weight | $60 → $65 | $65.13 | -0.20% | 7 | May 7, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $62 → $53 | $47.85 | +10.76% | 9 | Apr 28, 2025 | |
| IRWD Ironwood Pharmaceuticals | Downgrades: Equal-Weight | $7 → $1 | $1.09 | -8.26% | 4 | Apr 15, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $970 → $1,100 | $660.49 | +66.54% | 17 | Mar 5, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $120 → $140 | $120.14 | +16.53% | 11 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $210 → $240 | $201.47 | +19.12% | 8 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $165 → $140 | $135.19 | +3.56% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $130 → $170 | $117.12 | +45.15% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $335 → $280 | $289.33 | -3.22% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $26.87 | +11.65% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $21.97 | +218.62% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $27 | $18.05 | +49.58% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $90 | $58.30 | +54.37% | 5 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $25.16 | +19.24% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $131.62 | +29.16% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $13.56 | +99.12% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $10.66 | +17,489.12% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.81 | +4,340.61% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $13.07 | +45.37% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $5 | $0.08 | +6,293.86% | 3 | Apr 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.17 | +5,028.21% | 4 | Dec 3, 2019 |
Vertex Pharmaceuticals
Aug 6, 2025
Upgrades: Overweight
Price Target: $460
Current: $395.92
Upside: +16.19%
BioNTech SE
Aug 5, 2025
Maintains: Overweight
Price Target: $170 → $150
Current: $112.78
Upside: +33.00%
Merck & Co.
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $97 → $90
Current: $82.71
Upside: +8.81%
Regeneron Pharmaceuticals
May 30, 2025
Downgrades: Equal-Weight
Price Target: $700 → $580
Current: $561.55
Upside: +3.29%
Xenon Pharmaceuticals
May 13, 2025
Maintains: Overweight
Price Target: $50 → $47
Current: $37.67
Upside: +24.77%
Halozyme Therapeutics
May 7, 2025
Maintains: Equal-Weight
Price Target: $60 → $65
Current: $65.13
Upside: -0.20%
Bristol-Myers Squibb Company
Apr 28, 2025
Maintains: Equal-Weight
Price Target: $62 → $53
Current: $47.85
Upside: +10.76%
Ironwood Pharmaceuticals
Apr 15, 2025
Downgrades: Equal-Weight
Price Target: $7 → $1
Current: $1.09
Upside: -8.26%
Eli Lilly and Company
Mar 5, 2025
Maintains: Overweight
Price Target: $970 → $1,100
Current: $660.49
Upside: +66.54%
Gilead Sciences
Mar 5, 2025
Maintains: Overweight
Price Target: $120 → $140
Current: $120.14
Upside: +16.53%
Mar 5, 2025
Maintains: Overweight
Price Target: $210 → $240
Current: $201.47
Upside: +19.12%
Feb 13, 2025
Maintains: Equal-Weight
Price Target: $165 → $140
Current: $135.19
Upside: +3.56%
Feb 13, 2025
Upgrades: Overweight
Price Target: $130 → $170
Current: $117.12
Upside: +45.15%
Jan 10, 2025
Maintains: Equal-Weight
Price Target: $335 → $280
Current: $289.33
Upside: -3.22%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $26.87
Upside: +11.65%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $21.97
Upside: +218.62%
Oct 21, 2024
Upgrades: Overweight
Price Target: $9 → $27
Current: $18.05
Upside: +49.58%
Sep 17, 2024
Maintains: Overweight
Price Target: $115 → $90
Current: $58.30
Upside: +54.37%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $25.16
Upside: +19.24%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $131.62
Upside: +29.16%
Mar 7, 2023
Initiates: Overweight
Price Target: $27
Current: $13.56
Upside: +99.12%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $10.66
Upside: +17,489.12%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $0.81
Upside: +4,340.61%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $13.07
Upside: +45.37%
Apr 27, 2020
Maintains: Buy
Price Target: $8 → $5
Current: $0.08
Upside: +6,293.86%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.17
Upside: +5,028.21%